---
search:
  boost: 2 
---

# Androgens

This is a subcategory of Endocrine Agents.

## Formulary

### Preferred

| Preferred                                 | Generic Name | Quantity | Time (Days) |
| :---------------------------------------- | :----------- | :------: | :---------: |
| Androderm <sup>AR PA</sup>                |              |          |             |
| Testosterone Gel 1% <sup>AR PA</sup>      |              |          |             |
| Testosterone Gel 1% Pump <sup>AR PA</sup> |              |          |             |

### Non-Preferred

| Non-Preferred                              | Generic Name | Quantity | Time (Days) |
| :----------------------------------------- | :----------- | :------: | :---------: |
| Jatenzo <sup>AR</sup>                      |              |          |             |
| Methyltestosterone <sup>AR</sup>           |              |          |             |
| Natesto <sup>AR</sup>                      |              |          |             |
| Testopel <sup>AR</sup>                     |              |          |             |
| Testosterone Cypionate <sup>AR</sup>       |              |          |             |
| Testosterone Gel 1.62% <sup>AR</sup>       |              |          |             |
| Testosterone Gel 2% <sup>AR</sup>          |              |          |             |
| Testosterone Sol 30 MG / ACT <sup>AR</sup> |              |          |             |
| Tlando <sup>AR</sup>                       |              |          |             |
| Xyosted <sup>AR</sup>                      |              |          |             |

## Length of Authorizations

365 Days

**All Authorizations**

Must be prescribed in accordance with FDA approved labeling

## Additional Criteria

### Clinical PA

-   Must provide documentation of lab work to support the need for testosterone supplementation

### Non-Preferred

-   Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred dug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    -   For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage
-   Must have had an inadequate clinical response of at least **90 days** with **all preferred** drugs
    -   For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    -   For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

-   Must provide documentation of patientâ€™s clinical response to treatment and ongoing safety monitoring (i.e., testosterone and hematocrit)

**AR** - All drugs: a PA is required for patients younger than 18 years

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=51)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=20)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
